Greiner Bio-One North America, Inc. sponsors effoerts to to advance HTS 3D spheroid based technology aimed at early drug discovery and clinical cancer biology.

MONROE, NORTH CAROLINA, UNITED STATES, September 16, 2016 /EINPresswire.com/ -- Greiner Bio-One North America, Inc. (GBO) is a proud sponsor of a National Institutes of Health-funded collaborative effort between Scripps Florida, Cold Springs Harbor Laboratory (CSHL), and Nano3D Biosciences, Inc. (n3D) to advance high-throughput screening (HTS) 3D spheroid based technology aimed at early drug discovery and clinical cancer biology.

This work will involve the development of 3D spheroid technologies into 384-well and 1,536-well formats that are automation amenable for HTS drug screening. This could be transformative not only for drug repurposing to fight cancer, but also for tapping a clinical component for precision medicine testing.

Principal and co-investigators for the study are Timothy Spicer and Louis Scampavia, faculty members in the Department of Molecular Therapeutics at The Scripps Research Institute (TSRI) in Jupiter, Florida, and Dr. Glauco Souza, President and CSO of n3D and Adjunct Assistant Professor at University of Texas Health Science Center in Houston.

GBO will supply the proprietary 384- and 1,536-well black/clear flat-bottom cell-repellent surface microplates utilized for the duration of the research project. GBO North American President of Sales and Marketing and Chairman of the Board, A.C. Marchionne, stated: “Our goal at GBO is the same as TSRI and n3D Biosciences, to accelerate drug discovery using advancements in microplate development that enable cell based assays and molecular manipulation of cancer biology.”

“This 3-year project will further validate and showcase magnetic 3D bioprinting technology in tandem with GBO’s high-optical quality plates as a powerful tool for HTS. We plan to implement a 1,536-well system in the early stages of this project, which will further set us apart from other 3D cell culturing and 3D bioprinting techniques,” said Souza.

For their part, Spicer and Scampavia hope n3D’s technology will facilitate a more complete understanding of how drug discovery researchers who work with clinicians should leverage the use of new and currently available drugs.

In this work n3D’s magnetic 3D bioprinting technology is providing a strategic advantage, since it is rapid and relatively easy, and presents a reproducible method to print 3D cultures in high throughput.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R33CA206949. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Greiner Bio-One North America, Inc. is a privately held plastics manufacturing company located in Monroe, NC, whose divisions manufacture a variety of products for the medical and research fields. Product applications include cultivation and analysis of cell and tissue cultures, microplates for drug discovery and high-throughput screening, blood and specimen collection, detection of bacteria and viruses, as well as OEM applications within the diagnostics industry. As an international manufacturer with global reach, Greiner Bio-One provides manufacturing, distribution logistics and product application support to the world’s largest hospitals, pharmaceutical and biotechnology corporations.

For more information about Greiner Bio-One North America, Inc., please visit, https://www.gbo.com/en_US.html

Mackenzie Farone-Waite
Greiner Bio-One North America, Inc.
7042387646
email us here